C

CVRx Inc
NASDAQ:CVRX

Watchlist Manager
CVRx Inc
NASDAQ:CVRX
Watchlist
Price: 12.49 USD 1.3% Market Closed
Market Cap: 325.2m USD

CVRx Inc
Investor Relations

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.

Show more
Loading

Earnings Calls

2024 Q4
Feb 12, 2025
Show Transcript
Previous
Next
Camtek Reports Strong Growth and Positive Outlook for HPC Market
2024 Q4
Feb 12, 2025

Camtek concluded 2024 with a record revenue of $429 million, reflecting a 36% year-over-year increase, alongside a 56% rise in operating income to $130 million. In Q4 alone, revenue hit $117 million, up 32% from the previous year. Looking ahead, Camtek expects revenues between $118-$120 million for Q1 2025, driven by robust demand in high-performance computing (HPC), which is projected to contribute at least 50% to business in the first half. Recent orders over $10 million bolster confidence in continued HPC growth as Camtek plans to launch advanced systems to capture this expanding market.

Show Full Analysis

Management

Mr. Kevin Hykes
President, CEO & Director
No Bio Available
Mr. Jared Oasheim
Chief Financial Officer
No Bio Available
Mr. Paul Verrastro
Chief Marketing & Strategy Officer
No Bio Available
Mr. Paul Pignato
Vice President of Operations
No Bio Available
Ms. Jonelle R. Burnham
VP & General Counsel
No Bio Available
Ms. Tonya A. Austin SPHR
Chief Human Resources Officer
No Bio Available
Ms. Jennifer E. Englund
Senior Vice President of Global Clinical Affairs
No Bio Available
Dr. Philip B. Adamson M.D., M.Sc.
Chief Medical Officer
No Bio Available
Ms. Bonnie Handke M.B.A., R.N.
Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics
No Bio Available
Mr. Robert Allen John
Chief Revenue Officer
No Bio Available

Contacts

Address
MINNESOTA
Minneapolis
9201 West Broadway Avenue, Suite 650
Contacts
+17634162850.0
www.cvrx.com